Vol. 6 No. 2 (2026)
Reimbursement Recommendations

Guanfacine Extended Release

decorative image of the issue cover

Published February 12, 2026

Key Messages

  • The Formulary Management Expert Committee (FMEC) recommends that guanfacine extended release (XR) be reimbursed for monotherapy of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years to 17 years, provided certain conditions are met.
  • Guanfacine XR may be reimbursed for monotherapy of ADHD in children and adolescents aged 6 years to 17 years, provided they meet the following conditions: the individual has experienced intolerable adverse events with at least 1 amphetamine-based psychostimulant and 1 methylphenidate-based psychostimulant that require discontinuation, or the individual has contraindications to the use of psychostimulants. Guanfacine XR should be discontinued if there are unacceptable toxicities. Guanfacine XR must represent good value to the drug plans.